All stories tagged :
Biz in Saigon
Featured
Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a...
ATRN-119, our ATR inhibitor, exhibits early evidence of single agent, anti-tumor activity and is progressing toward the recommended Phase 2 dose (RP2D) in the ongoing ABOYA-119 clinical trial Three patients in the 550 mg twice daily cohort in the ongoing...